Stratose to Cover CombiMatrix's Microarray Testing Services | GenomeWeb

NEW YORK (GenomeWeb News) – CombiMatrix said today that it has entered into an agreement with Stratose to provide coverage for its menu of diagnostic laboratory services, including its CombiSNP chromosomal microarray test.

Atlanta-based Stratose maintains a large preferred provider organization network in the US, including more than 850,000 direct and affiliate medical, dental, and workers' compensation provider contracts. Members of these plans will now have access to CombiMatrix's suite of tests for use in prenatal, miscarriage, and pediatric healthcare.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.